359 related articles for article (PubMed ID: 27436852)
1. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
Suarez-Alvarez B; Morgado-Pascual JL; Rayego-Mateos S; Rodriguez RM; Rodrigues-Diez R; Cannata-Ortiz P; Sanz AB; Egido J; Tharaux PL; Ortiz A; Lopez-Larrea C; Ruiz-Ortega M
J Am Soc Nephrol; 2017 Feb; 28(2):504-519. PubMed ID: 27436852
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
Wu X; Qi J; Bradner JE; Xiao G; Chen LF
J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
[TBL] [Abstract][Full Text] [Related]
3. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
4. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.
Belkina AC; Nikolajczyk BS; Denis GV
J Immunol; 2013 Apr; 190(7):3670-8. PubMed ID: 23420887
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of BET protein BRD4 delays murine lupus.
Wei S; Sun Y; Sha H
Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
[TBL] [Abstract][Full Text] [Related]
6. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.
Rudman MD; Choi JS; Lee HE; Tan SK; Ayad NG; Lee JK
Exp Neurol; 2018 Nov; 309():181-192. PubMed ID: 30134146
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
9. BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy.
Antolic A; Wakimoto H; Jiao Z; Gorham JM; DePalma SR; Lemieux ME; Conner DA; Lee DY; Qi J; Seidman JG; Bradner JE; Brown JD; Haldar SM; Seidman CE; Burke MA
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32603312
[TBL] [Abstract][Full Text] [Related]
10. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
11. Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.
Khan YM; Kirkham P; Barnes PJ; Adcock IM
PLoS One; 2014; 9(4):e95051. PubMed ID: 24759736
[TBL] [Abstract][Full Text] [Related]
12. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibition of MYC-amplified medulloblastoma.
Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
[TBL] [Abstract][Full Text] [Related]
14. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
15. BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis.
Zhou Y; Gu Y; Liu J
Biochem Biophys Res Commun; 2019 Nov; 519(3):481-488. PubMed ID: 31530390
[TBL] [Abstract][Full Text] [Related]
16. RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells.
Jung KH; Das A; Chai JC; Kim SH; Morya N; Park KS; Lee YS; Chai YG
J Neuroinflammation; 2015 Feb; 12():36. PubMed ID: 25890327
[TBL] [Abstract][Full Text] [Related]
17. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
18. BRD4 is a novel therapeutic target for liver fibrosis.
Ding N; Hah N; Yu RT; Sherman MH; Benner C; Leblanc M; He M; Liddle C; Downes M; Evans RM
Proc Natl Acad Sci U S A; 2015 Dec; 112(51):15713-8. PubMed ID: 26644586
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the acetyl lysine-binding pocket of bromodomain and extraterminal domain proteins interferes with adipogenesis.
Goupille O; Penglong T; Kadri Z; Granger-Locatelli M; Fucharoen S; Maouche-Chrétien L; Prost S; Leboulch P; Chrétien S
Biochem Biophys Res Commun; 2016 Apr; 472(4):624-30. PubMed ID: 26972250
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition.
Wang X; Zhou Y; Peng Y; Huang T; Xia F; Yang T; Duan Q; Zhang W
Exp Cell Res; 2019 Oct; 383(2):111507. PubMed ID: 31356816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
